JP7787190B2 - センタナファジン製剤ならびにその製造および使用方法 - Google Patents

センタナファジン製剤ならびにその製造および使用方法

Info

Publication number
JP7787190B2
JP7787190B2 JP2023547454A JP2023547454A JP7787190B2 JP 7787190 B2 JP7787190 B2 JP 7787190B2 JP 2023547454 A JP2023547454 A JP 2023547454A JP 2023547454 A JP2023547454 A JP 2023547454A JP 7787190 B2 JP7787190 B2 JP 7787190B2
Authority
JP
Japan
Prior art keywords
ctn
release
beads
weight
delayed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2023547454A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506595A (ja
JP2024506595A5 (enExample
Inventor
アズファー マティーン，サイード
クマール ミディドーディー，プラビーン
メロトラ，シャイリー
エリザベス ショーフ，スーザン
グプタ，サリン
海 鈴木
真裕 長谷川
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of JP2024506595A publication Critical patent/JP2024506595A/ja
Publication of JP2024506595A5 publication Critical patent/JP2024506595A5/ja
Priority to JP2025134582A priority Critical patent/JP2025183214A/ja
Application granted granted Critical
Publication of JP7787190B2 publication Critical patent/JP7787190B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
JP2023547454A 2021-02-23 2022-02-22 センタナファジン製剤ならびにその製造および使用方法 Active JP7787190B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025134582A JP2025183214A (ja) 2021-02-23 2025-08-13 センタナファジン製剤ならびにその製造および使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163152826P 2021-02-23 2021-02-23
US63/152,826 2021-02-23
US202163241839P 2021-09-08 2021-09-08
US63/241,839 2021-09-08
PCT/JP2022/007314 WO2022181625A1 (en) 2021-02-23 2022-02-22 Centanafadine pharmaceutical formulations, and methods of making and using same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025134582A Division JP2025183214A (ja) 2021-02-23 2025-08-13 センタナファジン製剤ならびにその製造および使用方法

Publications (3)

Publication Number Publication Date
JP2024506595A JP2024506595A (ja) 2024-02-14
JP2024506595A5 JP2024506595A5 (enExample) 2024-05-31
JP7787190B2 true JP7787190B2 (ja) 2025-12-16

Family

ID=80735736

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023547454A Active JP7787190B2 (ja) 2021-02-23 2022-02-22 センタナファジン製剤ならびにその製造および使用方法
JP2025134582A Pending JP2025183214A (ja) 2021-02-23 2025-08-13 センタナファジン製剤ならびにその製造および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025134582A Pending JP2025183214A (ja) 2021-02-23 2025-08-13 センタナファジン製剤ならびにその製造および使用方法

Country Status (11)

Country Link
US (6) US11564885B2 (enExample)
EP (1) EP4297734A1 (enExample)
JP (2) JP7787190B2 (enExample)
KR (1) KR20230152046A (enExample)
AU (1) AU2022227367A1 (enExample)
BR (1) BR112023015272A2 (enExample)
CA (1) CA3205786A1 (enExample)
IL (1) IL303767A (enExample)
MX (1) MX2023009833A (enExample)
TW (1) TW202302086A (enExample)
WO (1) WO2022181625A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023015272A2 (pt) * 2021-02-23 2023-11-07 Otsuka Pharma Co Ltd Formulações farmacêuticas de centanafadina e métodos de fabricação e uso das mesmas
KR20250053128A (ko) * 2022-08-24 2025-04-21 오츠카 세이야쿠 가부시키가이샤 센타나파딘을 포함하는 제약 조성물
US20250375418A1 (en) * 2022-09-02 2025-12-11 Otsuka Pharmaceutical Co., Ltd. 1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane for treating major depressive disorder
WO2025183181A1 (en) 2024-02-28 2025-09-04 Otsuka Pharmaceutical Co., Ltd. Use of centanafadine in treatment of adhd symptoms
US12502358B1 (en) 2024-08-13 2025-12-23 Innovate Therapeutics Llc Centanafadine multiphasic controlled-release pharmaceutical formulation
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
FR2471186A1 (fr) 1979-12-10 1981-06-19 Roussel Uclaf Nouveaux comprimes a delitescence colique, ainsi que leur procede de preparation
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
GB9416600D0 (en) * 1994-08-17 1994-10-12 Smithkline Beecham Plc Pharmaceutical formulation
US6132724A (en) 1998-04-29 2000-10-17 City Of Hope National Medical Center Allelic polygene diagnosis of reward deficiency syndrome and treatment
US8747895B2 (en) * 2004-09-13 2014-06-10 Aptalis Pharmatech, Inc. Orally disintegrating tablets of atomoxetine
WO2006133349A2 (en) 2005-06-08 2006-12-14 Alpharma, Inc. Orally disintegrable sleep aid formulations
EP1915146A4 (en) * 2005-07-27 2010-06-02 Dov Pharmaceutical Inc NOVEL 1-ARYL-3-AZABICYCLO [3.1.0] HEXANEES. PREPARATION AND USE FOR THE TREATMENT OF NEUROPSYCHIATRIC DISEASES
ES2529455T3 (es) * 2006-05-12 2015-02-20 Shire Llc Sistema de administración de fármacos por dosis controladas
US8846100B2 (en) * 2006-05-12 2014-09-30 Shire Llc Controlled dose drug delivery system
CN107335057A (zh) 2012-07-27 2017-11-10 韦尔斯利医药有限公司 用于缓解尿频的药物制剂及其使用方法
CN106029637A (zh) 2013-12-09 2016-10-12 纽罗万斯公司 新的组合物
EP3069715A1 (en) * 2015-03-20 2016-09-21 Salmon Pharma GmbH Immediate release dosage forms of Atomoxetine
US20180008575A1 (en) 2016-07-11 2018-01-11 Neurovance, Inc. Methods of treating binge eating disorder
BR112023015272A2 (pt) * 2021-02-23 2023-11-07 Otsuka Pharma Co Ltd Formulações farmacêuticas de centanafadina e métodos de fabricação e uso das mesmas

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140206740A1 (en) 2011-07-30 2014-07-24 Neurovance, Inc. Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters

Also Published As

Publication number Publication date
AU2022227367A1 (en) 2023-08-03
US20250041225A1 (en) 2025-02-06
US11564885B2 (en) 2023-01-31
US20230338293A1 (en) 2023-10-26
MX2023009833A (es) 2023-09-04
TW202302086A (zh) 2023-01-16
US20240165030A1 (en) 2024-05-23
JP2024506595A (ja) 2024-02-14
EP4297734A1 (en) 2024-01-03
US11980690B2 (en) 2024-05-14
US12156941B2 (en) 2024-12-03
AU2022227367A9 (en) 2024-10-17
US11759426B2 (en) 2023-09-19
IL303767A (en) 2023-08-01
JP2025183214A (ja) 2025-12-16
US20250319030A1 (en) 2025-10-16
US20220265557A1 (en) 2022-08-25
BR112023015272A2 (pt) 2023-11-07
CA3205786A1 (en) 2022-09-01
WO2022181625A1 (en) 2022-09-01
US12370144B2 (en) 2025-07-29
US20230104529A1 (en) 2023-04-06
KR20230152046A (ko) 2023-11-02

Similar Documents

Publication Publication Date Title
JP7787190B2 (ja) センタナファジン製剤ならびにその製造および使用方法
CN1404389B (zh) 时控脉冲给药系统
JP4369752B2 (ja) プロプラノロールの時限徐放性多粒子剤型
CA2884901C (en) Timed, pulsatile release systems
CN101410094B (zh) 包含弱碱性选择性5-羟色胺5-ht3阻断剂和有机酸的药物递送系统
JP2005508922A6 (ja) プロプラノロールの時限徐放性多粒子剤型
CN102869349A (zh) 耐酒精的肠溶药物组合物
CN112789042A (zh) 用于治疗由毒蕈碱受体激活所缓解的障碍的组合物和方法
CN107205954A (zh) 特别用于治疗注意力缺陷障碍的方法和组合物
CN112043681A (zh) 一种拉考沙胺药物组合物及其药物制剂
KR20200013791A (ko) 파킨슨병의 고정용량 조합 치료법
US20050226927A1 (en) Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a GABAB receptor agonist
US20090136550A1 (en) Modified release formulations of diltiazem
MXPA06011322A (es) Formas de dosificacion farmaceutica que tienen propiedades de liberacion inmediata y/o liberacion controlada que contienen un agonista del receptor gabab.
EA052298B1 (ru) Фармацевтические составы центанафадина и способы их получения и применения
HK40098701A (zh) 森塔纳法啶药物制剂及其制备和使用方法
CN116710078A (zh) 森塔纳法啶药物制剂及其制备和使用方法
ZA200608190B (en) Controleld release dosage for GABA receptor antagonist
CA3210988A1 (en) Extended-release compositions comprising atomoxetine
AU2013273835B2 (en) Timed, pulsatile release systems
AU2013204408B2 (en) Drug delivery systems comprising weakly basic selective serotonin 5-HT3 blocking agent and organic acids
HK1108116B (en) Timed, pulsatile release systems

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240523

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240523

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20241115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250228

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250813

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251202

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251204

R150 Certificate of patent or registration of utility model

Ref document number: 7787190

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150